C2N Diagnostics Statement on FDA Accelerated Approval of Aducanumab forAlzheimer’s Treatment
ST. LOUIS -- C2N Diagnostics says the U.S. Food and Drug Administration’s (FDA) decision granting accelerated approval to aducanumab (Aduhelm) on the basis of amyloid plaque reduction for Alzheimer’s treatment represents a significant change in the ongoing fight against the horrible disease.
Dr. Joel Braunstein, C2N’s CEO, said, “The accelerated approval of aducanumab will offer a potential new option for patients, their families and clinicians to consider as part of a comprehensive care plan for Alzheimer’s disease. The FDA’s decision is consistent with C2N’s focus on the development and commercialization of impactful diagnostic tests that track the most important biological features of the disease. Starting with the PrecivityAD™ blood test, it’s possible to identify brain amyloid plaques from a single sample of blood and to aid in the early diagnosis of Alzheimer’s disease. Early intervention represents our greatest chance for delaying or halting future progression.”
The FDA said, “Patients receiving the [aducanumab] treatment had significant dose- and time-dependent reduction of amyloid beta plaque, while patients in the control arm of the studies had no reduction of amyloid beta plaque.”
The Wall Street Journal, in a recent editorial about the drug, directly linked it to blood tests: “[w]ith the advent of blood tests that can identify people at risk for Alzheimer’s years before symptoms occur, millions more Americans could eventually benefit.”
While the test by itself cannot diagnose Alzheimer’s disease — which is a clinical diagnosis made by a health care provider — the test is an important means for physicians to aid in the evaluation process.
The PrecivityAD™ test does not involve any radiation and is non-invasive. These features make the test more accessible than other diagnostic methods that physicians use to evaluate issues with memory and thinking.
The proprietary test involves a small blood sample from a person’s forearm. C2N analyzes the blood in its specialized laboratory facility using mass spectrometry to measure the concentrations of amyloid beta 42 and 40 (Aß42 and Aß40), and the presence of apolipoprotein E (ApoE) isoforms in blood. The analysis process is semi-automated and allows for C2N to process samples in a routine and repeatable manner.
C2N offers the test now in 48 states, the District of Columbia and Puerto Rico.
About C2N Diagnostics, LLC
C2N’s Diagnostics’ vision is to bring Clarity Through Innovation™. It focuses its therapeutic discovery efforts around mechanism-based approaches to prevent or stop the progression of human neurological disorders. Diagnostic efforts revolve around bringing accurate, widely accessible, and cost-effective blood tests to the clinic for the betterment of patient care and brain health monitoring. Its lead commercial product, PrecivityAD™, is a mass spectrometry-based test that measures in blood multiple analytes including Aβ42, Aβ40, and apolipoprotein E isoforms. This test predicts brain amyloid plaques as determined by PET scan results and in early 2019 it received a Breakthrough Device Designation from the U.S. Food and Drug Administration. For more information visit www.C2N.com.
-
Most popular related searches
Related products
Related news
-
New Research Demonstrates Clinical Utility of Daxor Corporation Blood Volume (BVA-100) Diagnostic in Neurocritical Care
Data Highlight Daxor’s Diagnostic Changes Care in 69% of Patients With Non-Traumatic Subarachnoid Hemorrhage (nSAH) Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement technology, today announces new data demonstrating the clinical utility of the BVA-100 blood test in patients with non-traumatic subarachnoid hemorrhage (nSAH) presented at the virtual NeuroCritical Care Society (NCS) 19th Annual Meeting. The study titled, “The Influence of Blood Volume Analysis on the...
-
C2N Opens State-of-the-Art CLIA Lab in St. Louis as Alzheimer’s Disease Blood Diagnostic Test Bests Others in Independent Comparison Studies Published in JAMA Neurology
On World Alzheimer’s Day, Missouri leaders and economic development officials praise C2N Diagnostics for deciding to continue to grow its St. Louis-based company which is receiving international recognition for developing and accelerating novel diagnostics and therapies for Alzheimer’s disease. C2N Diagnostics has expanded its lab facilities to 13,320 square feet in the Cortex Innovation Community at 4340 Duncan Ave. The company is using this start-of-the-art federally regulated CLIA lab for its...
-
Avery Biomedical Devices’ Nextgen Diaphragm Pacing Transmitter, Spirit, Earns FDA Approval – Now Available
Avery Biomedical Devices (Commack, NY), the global leader in high reliability diaphragm pacemakers, announced that its new diaphragm pacemaker transmitter, Spirit, has earned FDA approval and is now being offered to patients using its pacing system. This NextGen transmitter features a light-weight compact design with easy-to-use touch controls and offers precision-enhancing digital circuitry. Avery Chief Executive Officer Linda Towler stated, “At Avery, our R&D activities have always been focused on...
-
Two Research Studies Bolster Method That C2N’s PrecivityAD Blood Test Uses to Aid Clinicians in Alzheimer’s Disease Diagnoses
Two recent studies demonstrated that the scientific method that serves as the basis for C2N Diagnostics’ PrecivityAD™ blood test scored best compared to others assays in their respective ability to identify amyloid plaque. The C2N Diagnostics PrecivityAD™ blood test that clinicians use to aid in diagnosing Alzheimer’s disease is underpinned by the liquid chromatography–mass spectrometry (LC-MS/MS) assay that Dr. Randall J. Bateman and his laboratory developed at Washington University....
-
BlueRock Therapeutics Receives FDA Fast Track Designation for DA01 in the Treatment of Advanced Parkinson`s Disease
BlueRock Therapeutics LP, a clinical stage biopharmaceutical company and wholly owned subsidiary of Bayer AG, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for DA01 for advanced Parkinson’s disease (PD). DA01, BlueRock’s pluripotent stem cell-derived dopaminergic neuron therapy, is under evaluation in a Phase 1 study. The FDA’s Fast Track designation is intended to facilitate the development and review of drug candidates that treat serious condition...
Customer comments
No comments were found for C2N Diagnostics Statement on FDA Accelerated Approval of Aducanumab forAlzheimer’s Treatment. Be the first to comment!